
Sign up to save your podcasts
Or


Arnon Kater joins Daniela Marin of The Lancet Haematology to discuss the phase 1b/2 EPCORE CLL-1 trial of epcoritamab monotherapy for Richter transformation, which is being presented at ASH 2025.
Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00327-8/fulltext
Continue this conversation on social!
By The Lancet GroupArnon Kater joins Daniela Marin of The Lancet Haematology to discuss the phase 1b/2 EPCORE CLL-1 trial of epcoritamab monotherapy for Richter transformation, which is being presented at ASH 2025.
Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00327-8/fulltext
Continue this conversation on social!

22 Listeners

0 Listeners

0 Listeners

3 Listeners

1 Listeners

0 Listeners

1 Listeners

0 Listeners

0 Listeners

1 Listeners

1 Listeners

1 Listeners

0 Listeners

0 Listeners

0 Listeners

0 Listeners

0 Listeners

0 Listeners

0 Listeners